Abstract
In recent years, several antitumor signaling pathways mediated by the cGMP-dependent protein kinases have been identified in colon cancer cells. This review aims to present the mounting evidence in favor of cGMP/protein kinase G (PKG) signaling as a therapeutic strategy in colon cancer. The homeostatic and tumor suppressive effects of cGMP in the intestine are uncontested, but the signaling details are not understood. PKG is the central cGMP effector, and can block proliferation and tumor angiogenesis by inhibiting β-catenin/TCF and SOX9 signaling. Therapeutic activation of cGMP/PKG offers a promising avenue for the prevention and treatment of colon cancer, but additional preclinical studies are needed to fully understand the potential of this system.
Original language | English (US) |
---|---|
Pages (from-to) | 65-80 |
Number of pages | 16 |
Journal | Future Medicinal Chemistry |
Volume | 2 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2010 |
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery